CERo Therapeutics Holdings, Inc. (CERO) annual cash flow statement — 5-year operating, investing & financing history
| Cash from Operations | -14.4M | -16.08M | -5.79M | -5.79M | -1.09M | -697.11K |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -156.15% | -177.73% | 0% | -430.1% | -56.68% | - |
| Net Income | -20.7M | -19.92M | -8.3M | -7.29M | -11.83M | -10.63M |
| Depreciation & Amortization | 1.09M | 1.09M | 1.12M | 1.12M | 1.07M | 735.47K |
| Stock-Based Compensation | 3.12M | 1.1M | 96.9K | 96.9K | 381.07K | 287.74K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.62M | 1.47M | -536.85K | -254.61K | 6.87M | 9.27M |
| Working Capital Changes | 477.05K | 189.2K | 1.84M | 540.11K | 2.41M | -365.08K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.31M | 1.93M | 258.46K | 1.28M | 0 | 0 |
| Cash from Investing | 500K | 500K | 0 | -7.94K | 180.84M | -178.5M |
| Capital Expenditures | 0 | 0 | 0 | 0 | -694.23K | -612.57K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 8.69M | 181.86M | -177.89M |
| Cash from Financing | 9.55M | 13.92M | 571.68K | 571.68K | -138.7M | 180.3M |
| Debt Issued (Net) | 1.5M | 0 | -14.18K | 564.04K | 650K | 0 |
| Equity Issued (Net) | 6.45M | 14.02M | 13.73M | 7.64K | -139.35K | 180.3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -33.48K | -139.35M | 0 |
| Other Financing | 1.6M | -105.42K | -13.14M | 0 | -139.21M | 0 |
| Net Change in Cash | -4.35M | -1.66M | -5.22M | -5.22M | 41.04M | 1.1M |
| Free Cash Flow | -14.4M | -16.08M | -5.79M | -5.79M | -1.79M | -1.31M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -179.22% | -177.73% | 0% | -224.1% | -36.41% | - |
| FCF per Share | -0.50 | -3.80 | -47.93 | -787.43 | -242.96 | -178.11 |
| FCF Conversion (FCF/Net Income) | 0.70x | 0.81x | 0.75x | 2283.12x | 1.64x | 2.21x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CERO stock.
CERo Therapeutics Holdings, Inc. (CERO) generated $-16.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
CERo Therapeutics Holdings, Inc. (CERO) reported negative free cash flow of $16.1M in 2025, indicating capital requirements exceeded cash from operations.
CERo Therapeutics Holdings, Inc. (CERO) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.